Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis

Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review

(2014) Tatiana Cobo-Ibáñez et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4

(2013) Jan J.G.M. Verschuuren et al.   AUTOIMMUNITY REVIEWS

Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis

(2013) Valentina Catzola et al.   JOURNAL OF NEUROLOGY

Prolonged B-Cell Depletion in MuSK Myasthenia Gravis Following Rituximab Treatment

(2013) John S. Yi et al.   MUSCLE & NERVE

Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis

(2013) Feng Sun et al.   MUSCLE & NERVE

Myocardial infarction after rituximab infusion

(2013) Dimitri Renard et al.   NEUROMUSCULAR DISORDERS

Long-Lived Plasma Cells in Autoimmunity: Lessons from B-Cell Depleting Therapy

(2013) Matthieu Mahévas et al.   Frontiers in Immunology

Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

(2012) Matthew N Meriggioli et al.   Expert Review of Clinical Immunology

Pathogenic Long-Lived Plasma Cells and Their Survival Niches in Autoimmunity, Malignancy, and Allergy

(2012) O. Winter et al.   JOURNAL OF IMMUNOLOGY

Myasthenia gravis, castleman disease, pemphigus, and anti-phospholipid syndrome

(2012) Michala Jakubíková et al.   MUSCLE & NERVE

Long-lasting treatment effect of rituximab in MuSK myasthenia

(2012) J. Diaz-Manera et al.   NEUROLOGY

Rituximab in Severe Seronegative Juvenile Myasthenia Gravis: Review of the Literature

(2012) Roshan Koul et al.   PEDIATRIC NEUROLOGY

B-cell therapies in established rheumatoid arthritis

(2011) Maria J. Leandro et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis

(2011) T. Kuntzer et al.   NEUROLOGY

Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?

(2010) Maurizio Benucci et al.   AUTOIMMUNITY REVIEWS

Guidelines for treatment of autoimmune neuromuscular transmission disorders

(2010) G. O. Skeie et al.   EUROPEAN JOURNAL OF NEUROLOGY

Myasthenia gravis developing in a patient with CNS lymphoma

(2010) Rami Masroujeh et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis

(2010) A. Sadnicka et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis

(2010) H. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rituximab for myasthenia gravis

(2009) Karl Stieglbauer et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Rebooting the Immune System with High-Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis

(2008) Daniel B. Drachman et al.   Annals of the New York Academy of Sciences

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

(2008) R. Stasi et al.   BLOOD

A review of the current use of rituximab in autoimmune diseases

(2008) Hakan M. Gürcan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis

(2008) Samar Kerkeni et al.   MUSCLE & NERVE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE